Posts Tagged ‘cell and gene therapy’
Meet CGT Global’s Scientific Team: Vanessa Murillo – Supervisor, Client Scientific Associate Team
October 08, 2025 Written by: Joanna Wirkus, PhD At CGT Global, advancing scientific discoveries worldwide by delivering high-quality biospecimens starts with providing exceptional service to our clients. Today, we’re highlighting how this happens by speaking with Vanessa Murillo, a core member and leader of CGT Global’s Client Scientific Associate team. Vanessa is a Client Scientific…
For More Information5 Green Flags the FDA Looks for in CGT CMC and How to Get Them
Roughly 50–75% of FDA rejections in cell and gene therapy aren’t about safety or efficacy — they’re due to CMC and manufacturing deficiencies.In short, most programs don’t fail because the science doesn’t work — they fail because the manufacturing story isn’t strong enough.(Sources: Jefferies analysis of FDA complete response letters, FiercePharma 2024; multiple CMC audit…
For More InformationBaby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy
Written by Joanna Wirkus, PhD May 15, 2025, NPR ’s Science Friday spotlighted Baby KJ, the first infant to receive a personalized CRISPR-based gene editing treatment. The segment explored the groundbreaking therapy, the condition it aims to treat, and the collaborative effort behind this historic milestone. Here’s a summary of the key points from the…
For More InformationAlzheimer’s & Neurodegenerative Disease: A Global Challenge
Written by CGT Global Cell & Gene Therapy Is Shifting the Paradigm Recent CGT innovations are upending traditional models and opening new paths to treat or even reverse Alzheimer’s progression: 1. AAV-Based Gene Therapy (LX1001) 2. CRISPR-Engineered Microglia 3. Behavior-Reprogramming Gene Therapy (UC San Diego) 4. Stem Cells & MSC Therapies 5. iPSC TriCulture Models…
For More InformationCGT Global Appoints Dr. Andrew Branagan to Board of Advisors, Expanding Cell and Gene Therapy Expertise
CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today announced the appointment of Andrew Robert Branagan, MD, PhD, to its Board of Advisors. Dr. Branagan brings extensive expertise in hematologic malignancies, immunology, and the development of novel therapeutic strategies, including cellular therapies. This press release features…
For More InformationMeet CGT Global’s Scientific Team: Bryan Pulling – Laboratory Operations Manager
Written by Joanna Wirkus, PhD Every day at CGT Global, our experienced team collaborates to deliver high quality cells to scientists around the world. Success starts with the strength of our team and the dedication of the people who power it. In this edition of Meet the Scientific Team, we’re proud to spotlight Bryan Pulling…
For More InformationFast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More InformationHow Natural Killer Cells are Revolutionizing Cancer Treatment
By Joanna Wirkus What makes Natural Killer (NK) Cells the Perfect Weapon Against Cancer? Unlike the T cells of the adaptive immune system, innate natural killer (NK) cells protect the body against tumors without prior programming. They recognize and become activated by abnormal cells that lack or express key outer membrane markers characteristic of cancer.…
For More InformationHow to Improve Humanized Mouse Engraftment: CD34+ Cell Sourcing & Viability Tips
By: Joanna Wirkus Simple Steps to Significantly Improve Humanized Mice Engraftment Success Previously in “Overcoming Challenges with Animal Models in Research”, we covered why animal models with human immune systems have significantly improved the translation of preclinical findings into life-saving treatments. Successfully creating these advanced models for testing new therapies relies on high hematopoietic stem…
For More InformationCord Blood CD34+ Cells: High Viability for Humanized Mouse Models
By: Joanna Wirkus The Rise of Cord Blood CD34+ Cells in Humanized Mouse Models and Cell Therapy Innovation Scientists in the late 1980’s discovered that umbilical cord blood derived stem cells had high proliferative potential and tolerated cryopreservation and thawing (Broxmeyer, 1989). Building on this research, the first report of cord blood derived CD34+ human…
For More Information